Xinqiao Hospital Of Chongqing

This trial tests whether adding lumbrokinase, an enzyme derived from earthworms, to standard aspirin treatment can improve recovery in people who have had a moderate-to-severe ischemic stroke. Participants receive either lumbrokinase capsules or a placebo, along with aspirin, for…

This trial investigates whether adding tirofiban, a fast-acting anti-clotting drug, to standard aspirin treatment can improve recovery in people who have had a moderate ischemic stroke. Participants receive either tirofiban or a placebo, both with aspirin, within 24 hours of stro…

This trial tests whether a sublingual (under-the-tongue) tablet of edaravone dexborneol, given within 6 hours of stroke onset during transfer between hospitals, can improve functional recovery in people with acute ischemic stroke. About 1,040 participants will receive either the …

This early-phase study tests a new mRNA therapy that targets CD19, a protein on immune cells, to treat autoimmune diseases like lupus and immune anemia. The treatment uses lipid nanoparticles to deliver mRNA that helps the body clear harmful B cells. About 47 participants aged 14…

This early-phase trial tests an mRNA immunotherapy for people with tumors linked to the Epstein-Barr virus, such as nasopharyngeal cancer, gastric cancer, and lymphoma. The treatment aims to help the immune system recognize and attack cancer cells. Researchers will check safety a…

This study tests whether adding the drug eptifibatide after standard clot-dissolving treatment can help people with acute ischemic stroke recover better. It includes 786 adults who arrive at the hospital 4.5 to 24 hours after stroke symptoms start. The goal is to see if this comb…